Trick or trap by One Carbon Therapeutics

Read a short story of One-carbon Therapeutics achievements so far in Nature Biopharma Dealmakers ( We are working hard to bring our novel inhibitor into the clinic.

Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism

The One-carbon Therapeutics team is proud and excited to share our latest paper published inNature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitorTH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificityand emphasises the importance of utilising correct human-like conditions and cancer models in drugdevelopment. We show that cancer-specific […]

One-carbon Therapeutics receives US patent

We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the […]